The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1130
May 13, 2002
View Complete Issue         Table of Contents 2019 
Fondaparinux (Arixtra), A New Anticoagulant
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Fondaparinux (Arixtra), A New Anticoagulant
May 13, 2002 (Issue: 1130)
Fondaparinux (Arixtra - Organon Sanofi-Synthelabo), a synthetic analog of heparin, has been approved by the FDA for prevention of deep vein thrombosis (DVT) after hip fracture surgery or knee or hip replacement.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Fondaparinux (Arixtra), A New Anticoagulant
Article code: 1130a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.